Pörssitiedote9.11.2023 klo 21.15RLS Global AB: RLS Global initiates strategic review process aiming to commercialize ChloraSolv
Pörssitiedote9.11.2023 klo 21.00RLS Global AB: RLS Global and Convatec have agreed to terminate collaboration agreement
Lehdistötiedote6.9.2023 klo 7.00RLS Global AB: First patient included in new clinical investigation on pressure ulcers
Lehdistötiedote1.9.2023 klo 11.00RLS Global AB: ChloraSolv recommended for UK CA certification required for UK market after Brexit
Pörssitiedote25.8.2023 klo 7.00RLS Global AB: RLS GLOBAL AB (publ) PUBLISHES INTERIM REPORT FOR THE PERIOD APRIL-JUNE 2023
Pörssitiedote24.8.2023 klo 16.30RLS Global AB: RLS GLOBAL AB (PUBL) RAISES A SHORT-TERM LOAN OF MSEK 5.0
Pörssitiedote22.8.2023 klo 13.00RLS Global AB: RLS Global appoints Torbjörn Sannerstedt as new Chief Financial Officer
Lehdistötiedote1.6.2023 klo 10.55Redeye: RLS Global Q1 2023: Delay in Europe but progress in the Middle East
Lehdistötiedote20.3.2023 klo 10.00RLS Global AB: ChloraSolv shows notably greater antibiofilm activity in vitro compared to other debridement products in published article
Lehdistötiedote1.3.2023 klo 13.48Redeye: RLS Global Q4 2022 - No surprises – but expectations of an eventful 2023
Pörssitiedote24.1.2023 klo 20.40Lars Johansson nominated as new Chairman of the Board of RLS Global AB
Lehdistötiedote9.12.2022 klo 8.00RLS Global AB: RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases
Lehdistötiedote10.11.2022 klo 10.00Presentation by Björn Larsson, CEO, RLS Global AB, about the company's operations and the currently ongoing rights issue
Lehdistötiedote4.11.2022 klo 13.30RLS Global AB: RLS Global's CEO Björn Larsson interviewed by Erik Penser Bank about the ongoing rights issue